Principal Financial Group Inc. Has $45.53 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Principal Financial Group Inc. lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 12.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 679,167 shares of the medical device company’s stock after selling 95,415 shares during the period. Principal Financial Group Inc. owned approximately 0.17% of DexCom worth $45,531,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Blue Whale Capital LLP lifted its holdings in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after acquiring an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC grew its stake in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after buying an additional 11,075 shares during the last quarter. Brooktree Capital Management acquired a new position in shares of DexCom during the third quarter worth $683,000. National Pension Service lifted its stake in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after acquiring an additional 37,363 shares during the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in shares of DexCom during the 3rd quarter valued at $650,000. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 5.6 %

NASDAQ:DXCM opened at $80.04 on Monday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $31.26 billion, a price-to-earnings ratio of 47.93, a PEG ratio of 2.46 and a beta of 1.12. The firm has a fifty day simple moving average of $74.53 and a two-hundred day simple moving average of $82.62.

Analyst Ratings Changes

Several equities analysts have commented on DXCM shares. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Wells Fargo & Company lifted their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Leerink Partners decreased their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.